CN115671036A - Gel medicine for treating fundus and intraocular diseases - Google Patents
Gel medicine for treating fundus and intraocular diseases Download PDFInfo
- Publication number
- CN115671036A CN115671036A CN202211422822.XA CN202211422822A CN115671036A CN 115671036 A CN115671036 A CN 115671036A CN 202211422822 A CN202211422822 A CN 202211422822A CN 115671036 A CN115671036 A CN 115671036A
- Authority
- CN
- China
- Prior art keywords
- gel
- treatment
- drug
- fundus
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 24
- 201000010099 disease Diseases 0.000 title claims abstract description 20
- 239000000499 gel Substances 0.000 claims abstract description 56
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims abstract description 44
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims abstract description 44
- 229940079593 drug Drugs 0.000 claims abstract description 44
- 239000000017 hydrogel Substances 0.000 claims abstract description 26
- VQODGRNSFPNSQE-DVTGEIKXSA-N betamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-DVTGEIKXSA-N 0.000 claims description 24
- 229950006991 betamethasone phosphate Drugs 0.000 claims description 24
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 21
- 239000001110 calcium chloride Substances 0.000 claims description 21
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 21
- 229960003876 ranibizumab Drugs 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 2
- 230000009471 action Effects 0.000 abstract description 3
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 4
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000003161 choroid Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000000649 photocoagulation Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002121 nanofiber Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention provides a gel drug for treating fundus and intraocular diseases, which comprises an injectable hydrogel and a drug for treating choroidal neovascularization. The gel drug provided by the invention can reduce the dosage of the anti-VEGF drug, prolong the action time of the anti-VEGF drug and reduce the administration frequency of the anti-VEGF drug.
Description
Technical Field
The invention relates to a medicine, in particular to a medicine for treating fundus and intraocular diseases, and particularly relates to a gel medicine for treating choroidal neovascular diseases.
Background
The fundus choroid is a highly vascularized tissue that serves primarily to provide adequate nutrients for the retinal photoreceptors and retinal pigment epithelium, and may serve to clear the retina of metabolic waste products. Choroidal disorders are primarily characterized by progressive dysfunction of retinal pigment epithelial cells, and by abnormalities in choroidal vascular structure and function that cause choroidal vascular disease, such as Polypoidal Choroidal Vasculopathy (PCV), central serous chorioretinopathy, and age-related macular degeneration-related Choroidal Neovascularization (CNV). A large number of studies indicate that the choroidal vascular disease has a wide range of effects and the incidence rate increases exponentially. The pathological processes of choroidal vascular diseases mainly include increased vascular permeability and neovascularization, leading to severe impairment of visual function and even irreversible blindness. CNV refers to the growth of new blood vessels from the choroid to the neural retina under the macula, causing macular edema, exudation, hemorrhage, photoreceptor injury, and eventually the formation of the final stage fibrotic scar-currently, methods of treatment for CNV include laser photocoagulation, vitrectomy, and intravitreal injection of anti-Vascular Endothelial Growth Factor (VEGF). However, laser photocoagulation and vitrectomy procedures have limited effectiveness and these procedures can damage the retina and blood vessels. Although currently effective in anti-VEGF therapy, a number of problems continue to exist, for example, frequent intravitreal injections of anti-VEGF drugs can lead to cataracts, glaucoma, endophthalmitis, uveitis, and retinal detachment. Importantly, the burden of frequent intravitreal injections can significantly reduce patient compliance. Furthermore, anti-VEGF has no effect on fibrotic scarring and may even impair the long-term viability of the choroid and retina. Therefore, intensive research into the pathogenesis of CNV, finding new effective therapeutic approaches and solutions, and increasing the anti-angiogenic therapeutic level of CNV is urgently needed.
Although the etiology is unclear, inflammation plays a crucial role in the development of CNV. In particular, previous studies have shown that proinflammatory cytokines such as interleukin-6 (IL-6) and interleukin-8 (IL-8) generally promote the development and/or progression of CNV. In addition, oxidative stress-induced damage is considered to be a key factor in Retinal Pigment Epithelium (RPE) degeneration, which is another important factor in the progression of CNV. Studies have shown that excessive inflammation-associated Reactive Oxygen Species (ROS) and oxidized lipoproteins lead to protein misfolding, aggregation and chronic activation of the innate immune response, positively correlated with pathological angiogenesis of CNV. In addition, ROS significantly promotes the expression of Vascular Endothelial Growth Factor (VEGF) in the retina. Thus, anti-inflammatory therapy and effective scavenging of ROS may be key strategies for CNV treatment.
Ranibizumab (trade name Lucentis) is a monoclonal antibody Fragment (FAB) that is obtained from the same parent murine antibody as bevacizumab. The ranibizumab is a typical anti-VEGF drug, can inhibit the vascular endothelial growth factor A in a targeted manner, and can delay the progress of neovascular diseases by inhibiting the proliferation of vascular endothelial cells and the formation of new blood vessels. At present, the mode of treating CNV by using ranibizumab is to directly inject the ranibizumab into vitreous body, and the ranibizumab has large dosage, short action time, needs to be administered once per month and is frequently administered.
Disclosure of Invention
In view of the above-mentioned defects of the prior art, the present invention provides a drug gel mixture for treating fundus and intraocular diseases, and aims to solve the technical problems of reducing the dosage of an anti-VEGF drug, increasing the action time of the anti-VEGF drug, and reducing the administration frequency of the anti-VEGF drug.
In order to solve the problems, the invention adopts the technical scheme that: a gel medicament for the treatment of ocular fundus and intraocular diseases, the gel medicament comprising an injectable hydrogel and a medicament for the treatment of choroidal neovascular diseases.
Preferably, the drug for treating choroidal neovascular disorders is an anti-VEGF drug.
Preferably, the drug for treating choroidal neovascular disorders is ranibizumab.
Preferably, in the gel medicament, the mass content of the ranibizumab is more than 1%.
Preferably, the method of preparing the injectable hydrogel comprises: the betamethasone disodium phosphate and the calcium chloride are mixed into a solution so that the mixed solution is converted into a gel.
Preferably, the ratio of the molar concentrations of betamethasone phosphate disodium and calcium chloride is 0.9-1.1.
Preferably, the molar concentrations of the betamethasone phosphate disodium and the calcium chloride are respectively more than 0.01M.
Preferably, the molar concentrations of the betamethasone phosphate disodium and the calcium chloride are respectively below 0.025M.
Preferably, the gel medication is configured to be injected with a 30G syringe and the liquid state returns to the gel state when the stress is removed.
The invention has the beneficial effects that: the invention provides a drug for treating choroidal neovascularization diseases, which has good biocompatibility, simple preparation and long efficacy, can continuously release an anti-VEGF drug for a long time to inhibit Choroidal Neovascularization (CNV) generation, can also remove Reactive Oxygen Species (ROS), and reduces local inflammation. The effective time of the traditional anti-VEGF drug treatment is remarkably prolonged. All components of the hydrogel can be applied to clinical application which can be easily converted into choroidal neovascular treatment by adopting clinically approved drugs, and can replace the current anti-VEGF drug treatment.
The conception, the specific structure and the technical effects of the present invention will be further described with reference to the accompanying drawings to fully understand the objects, the features and the effects of the present invention.
Drawings
FIG. 1 is a photograph showing the appearance of the hydrogel (0.0125M-BetP-Gel) formed in example 1, when the molar concentration of betamethasone disodium phosphate and calcium chloride reached 0.0125M.
FIG. 2 is a photograph showing the appearance of hydrogels formed by disodium betamethasone phosphate and calcium chloride at different molar concentrations (0.005M, 0.01M,0.0125M,0.025, 0.05M) in example 1.
FIG. 3 shows a transmission electron microscope (TEM image) of 0.0125M-BetP-Gel in example 1.
Figure 4 shows the rheological behaviour of 0.0125M-BetP-Gel in example 1.
FIG. 5 shows an element mapping image of 0.0125M-BetP-Gel in example 1.
FIG. 6 shows 0.0125M-BetP-Gel and Ca in example 1 2+ Photographs of the results of chelating agent ethylenediaminetetraacetic acid (EDTA) incubation.
FIG. 7 shows fluorescence images of IgG-loaded betamethasone phosphate hydrogel (IgG @ BetP-Gel) in example 2. Wherein, the left image is a bright field image, the middle image is a fluorescence image, and the right image is a combined image.
FIG. 8 shows the rheological behavior of IgG @ BetP-Gel in example 2. Wherein, G': storage modulus; g': loss modulus.
FIG. 9 shows the cumulative release profile of IgG after incubation of IgG @ BetP-Gel in PBS at 37 ℃ for 72h in example 2.
FIG. 10 shows photographs of the degradation of gG @ BetP-Gel in example 2 in PBS solution (left) and deionized water (right).
FIG. 11 shows the retention of IgG-Cy5.5 in vivo at various time points after intravitreal injection of free IgG-Cy5.5 or IgG-Cy5.5@ BetP-Gel in example 2.
FIG. 12 shows the results of the qPCR analysis of ZO-1, RPE65 and recovein mRNA expression levels in choroidal tissues in example 4, where the left bar data are untreated mouse (untreated) results, the middle bar data are control CNV mouse results, and the right bar data are gel drug injected CNV mouse results.
FIG. 13 shows the results of the western blot analysis of ZO-1, RPE65 and recovein mRNA expression levels in choroidal tissues in example 4, with untreated mice (untrained) results on the left, control CNV mice in the middle and gel drug injected CNV mice on the right.
Fig. 14 shows fluorescein angiographic images of CNV mice treated with four agents in example 5, where representative Infrared (IR) fundus and FA images show choroidal neovascular leakage before and after injection. Wherein, the four reagents are respectively: physiological Saline (Saline), 0.0125M-BetP-Gel prepared in example 1, anti-VEGF ranibizumab (Anti-VEGF, 10 mg/ml), and the Gel drug prepared in example 3 (Anti-VEGF @ BetP-Gel).
Figure 15 shows images of IB4 (biomarker of neovascularisation) staining of RPE/choroidal patches following treatment of CNV mice with the four agents of example 5, where IB4 staining in differently treated eyes revealed the CNV region.
Fig. 16 shows the quantitative results of the CNV region of the image shown in fig. 15.
Detailed Description
Example 1 preparation and characterization of hydrogels
After the applicant finds out that when the ratio of the molar concentration of the betamethasone disodium phosphate to the molar concentration of the calcium chloride is 0.9-1.1-0.9, hydrogel (BetP-Gel) can be formed in a few seconds. Particularly, when the ratio of the molar concentration of the betamethasone disodium phosphate to the molar concentration of the calcium chloride is 1. The lowest gelation concentration is about 0.01M each of betamethasone disodium phosphate and calcium chloride; when the molar concentration of the betamethasone disodium phosphate and the calcium chloride reaches 0.0125M, the formed gel is convenient for vitreous cavity injection, has no toxic effect on tissues, and can achieve the purpose of gel slow release. FIG. 1 shows a photograph of the appearance of the Gel (0.0125M-BetP-Gel) formed when the molar concentration of betamethasone disodium phosphate and calcium chloride reached 0.0125M. FIG. 2 shows photographs of the appearance of gels formed by betamethasone phosphate disodium with calcium chloride at different molar concentrations (0.005M, 0.01M,0.0125M,0.025, 0.05M). FIG. 3 shows a transmission electron microscope (TEM image) of 0.0125M-BetP-Gel, from which it can be seen that the hydrogel formed is a nanofiber structure. Figure 4 shows the rheological behavior of 0.0125M-BetP-Gel, which further confirms the formation of a hydrogel that can be injected with a 30G syringe and which returns to the Gel state when the stress is removed. Through experiments, the applicant finds that when the molar concentration of the betamethasone phosphate disodium and the calcium chloride is 0.01M-0.025M, the formed hydrogel can be easily injected by a 30G syringe, and the liquid state is recovered to be a gel state after the stress is removed. Fig. 5 shows an element mapping image of 0.0125M-BetP-Gel, from which betamethasone phosphate and calcium ions are uniformly distributed in the network structure.
The inventor of the application further proves that the forming mechanism of the nanofiber hydrogel is phosphate and Ca through FTIR spectrum and XRD spectrum of the hydrogel 2+ Form coordinate bonds between them. If 0.0125M-BetP-Gel is mixed withCa 2+ Incubation with chelating agent ethylenediaminetetraacetic acid (EDTA) (FIG. 6) found that BetP-Gel rapidly transformed from hydrogel morphology to solution, further validating phosphate and Ca 2+ The synergy between them is responsible for the formation of the hydrogel network.
EXAMPLE 2 hydrogel ability to deliver antibodies
And mixing the betamethasone phosphate disodium, the IgG antibody and the calcium chloride in the solution to form the IgG-loaded betamethasone phosphate hydrogel (IgG @ BetP-Gel). Wherein, the molar concentration of the betamethasone disodium phosphate and the calcium chloride is 0.0125M, and the mass content of the IgG antibody is 1 percent, namely 10mg/g.
Goat anti-rabbit IgG H&L(Alexa 
488 Confocal imaging of antibody-stained IgG @ BetP-Gel frozen sections showed that IgG was evenly distributed among the formed IgG @ BetP-Gel (as shown in FIG. 7). The rheological properties of IgG-loaded BetP-Gel and IgG-unloaded BetP-Gel were similar, indicating that encapsulation of the antibody had no significant effect on hydrogel formation (as shown in figure 8). In addition, due to the phosphate under physiological conditions and Ca in the hydrogel 2+ There is a competitive interaction between them, and the encapsulated antibody can be gradually released as the BetP-Gel is degraded. In Phosphate Buffered Saline (PBS), betP-Gel degraded and released about 50% of the antibody continuously over 3 days (as shown in fig. 9, fig. 10).
To further test the potential of BetP-Gel for intraocular antibody delivery, applicants injected Cyanine 5.5 labeled IgG (free IgG-cy 5.5) or BetP hydrogel encapsulated IgG-Cy5.5 (IgG-Cy5.5 @BetP-Gel) intravitreally and monitored mice using a live fluorescence imaging system (Perkinelmer IVIS Lumina III) at various time points post injection. After 14 days of free IgG-Cy5.5 injection, the intraocular Cy5.5 signal disappeared, indicating that free antibody can rapidly diffuse from the outside of the eye. In sharp contrast, the fluorescent signal of IgG-Cy5.5 remains in the eye after injection of IgGCy5.5@ BetP-Gel. On day 14, intense fluorescent signals were still observed in IgGCy5.5@ BetP-Gel-treated mice (as shown in FIG. 11).
EXAMPLE 3 preparation of gel drug
Considering the rapid sol-gel transformation and shear dilution and self-healing capabilities of the hydrogels, applicants loaded anti-VEGF therapeutic drug ranibizumab in the BetP hydrogel for the treatment of the laser-induced mouse CNV model. Only needs to mix BetP solution containing antibody with CaCl 2 The antibody loading can be easily realized by mixing the solutions.
In this example, a hydrogel was formed as a Gel drug for choroidal neovascularization (Anti-VEGF @ betp-Gel) by mixing a clinical Anti-inflammatory drug, betamethasone disodium phosphate approved by the national drug administration for clinical use, a gold-standard Anti-neovascularization drug for CNV treatment (Anti-VEGF) ranibizumab, and calcium chloride in a solution. Wherein, the molar concentration of the betamethasone phosphate disodium and the calcium chloride is 0.0125M, and the mass content of the ranibizumab is 1%.
Example 4 protective Effect of gel drug on laser-induced mouse CNV model
Applicants tested the protective effect of the gel drug prepared in example 3 on a laser-induced mouse model of choroidal neovascularization. Seven days after the laser-induced model was established, the vitreous chamber of the left eye of the same mouse was injected with physiological saline, the right eye was injected with the gel drug prepared in example 1, and 28 days after administration, the choroids of different groups of mice were collected and further subjected to qPCR and western blot experiments (the experimental results are shown in fig. 12 and 13). Experiments prove that the expression levels of ZO-1, RPE65 and recovery mRNA and protein are obviously reduced after laser photocoagulation, and the expression levels of ZO-1, RPE65 and recovery mRNA and protein are obviously reversed after the intravitreal injection of the BetP-Gel, thereby powerfully indicating that the BetP-Gel has a protective effect on a laser-induced mouse CNV model.
Example 5 Long-term therapeutic Effect of gel drugs on laser-induced mouse CNV model
Four agents were injected intravitreally into CNV model mice and CNV leakage was detected at weeks 1, 2, and 4 post-treatment. Wherein, the four reagents are respectively: physiological Saline (Saline), 0.0125M-BetP-Gel prepared in example 1, anti-VEGF ranibizumab (Anti-VEGF, 10 mg/ml), and the Gel drug prepared in example 3 (Anti-VEGF @ BetP-Gel).
Figure 14 shows fluorescein angiographic images (FFA) of CNV mice treated with four agents. The Anti-vegf group showed the best effect in the initial stage of treatment in the vascular leakage area, but the effect gradually decreased in the later stage with the passage of time. In contrast, CNV mice treated with Anti-VEGF @ BetP-Gel showed a gradually increasing therapeutic effect with the degradation of BetP-Gel and the sustained release of Anti-VEGF drugs.
Applicants also assessed CNV lesion areas by IB4 (biomarker for neovasculature) staining of RPE/choroidal patches (results are shown in fig. 15). The results showed that, consistent with FFA results, CNV lesion area was minimal at week 2 in the anti-VEGF group. But as the anti-VEGF effect disappeared, the CNV lesion area increased again. In contrast, after intravitreal injection of Anti-VEGF @ BetP-Gel, the thickness and length of the CNV lesion gradually decreased after 4 weeks, although the treatment effect of CNV was not as good as Anti-VEGF at week 2. It is noteworthy that the therapeutic effect of Anti-VEGF @ BetP-Gel was significantly better than Anti-VEGF from week 2 onwards (results are shown in FIG. 16).
The research results jointly prove that Anti-VEGF treatment time of a mouse CNV model induced by laser can be effectively prolonged by significantly reducing vascular leakage and weakening CNV through Anti-VEGF @ BetP-Gel treatment. Anti-VEGF @ betp-Gel achieves good therapeutic effect for a long period of time, and has important clinical transformation value, because it can significantly reduce the administration times and dosage of Anti-VEGF, thereby greatly reducing the risk of side effects of current Anti-VEGF therapy CNV.
The foregoing detailed description of the preferred embodiments of the invention has been presented. It should be understood that numerous modifications and variations could be devised by those skilled in the art in light of the present teachings without departing from the inventive concepts. Therefore, the technical solutions available to those skilled in the art through logic analysis, reasoning and limited experiments based on the prior art according to the concept of the present invention should be within the scope of protection defined by the claims.
Claims (9)
1. A gel medicament for the treatment of ocular fundus and intraocular diseases, characterized in that it comprises an injectable hydrogel and a medicament for the treatment of choroidal neovascularization.
2. The gel drug for the treatment of ocular fundus and intraocular diseases according to claim 1, characterized in that said drug for the treatment of choroidal neovascular diseases is an anti-VEGF drug.
3. The gel medication for the treatment of fundus and intraocular diseases according to claim 1, wherein said medication for the treatment of choroidal neovascular diseases is ranibizumab.
4. The gel drug for the treatment of ocular fundus and intraocular diseases according to claim 1, wherein the mass content of ranibizumab in the gel drug is 1% or more.
5. The gel drug for the treatment of fundus and intraocular diseases according to claim 1, characterized in that the injectable hydrogel is prepared by a method comprising: the betamethasone disodium phosphate and the calcium chloride are mixed into a solution so that the mixed solution is converted into a gel.
6. The gel medication for the treatment of fundus and intraocular diseases according to claim 5, characterized in that the ratio of the molarity of betamethasone disodium phosphate and calcium chloride is 0.9-1.1.
7. The gel pharmaceutical for the treatment of ocular fundus and intraocular diseases of claim 5, wherein said betamethasone phosphate disodium and calcium chloride have molar concentrations above 0.01M, respectively.
8. The gel pharmaceutical for the treatment of ocular fundus and intraocular diseases of claim 5, wherein said betamethasone phosphate disodium and said calcium chloride are present in a molar concentration of 0.025M or less, respectively.
9. The gel medication for treating fundus and intraocular diseases of claim 5, wherein said gel medication is configured to be injected with a 30G syringe and when the stress is removed the liquid state returns to gel state.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211422822.XA CN115671036A (en) | 2022-11-15 | 2022-11-15 | Gel medicine for treating fundus and intraocular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211422822.XA CN115671036A (en) | 2022-11-15 | 2022-11-15 | Gel medicine for treating fundus and intraocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115671036A true CN115671036A (en) | 2023-02-03 |
Family
ID=85052700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211422822.XA Pending CN115671036A (en) | 2022-11-15 | 2022-11-15 | Gel medicine for treating fundus and intraocular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115671036A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| CN101426531A (en) * | 2006-04-21 | 2009-05-06 | 东兴药品工业株式会社 | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation |
| US20090226519A1 (en) * | 2005-04-19 | 2009-09-10 | Charles Claude | Hydrogel bioscaffoldings and biomedical device coatings |
| CN102144961A (en) * | 2003-09-18 | 2011-08-10 | 参天制药株式会社 | Transscleral delivery |
| KR101306748B1 (en) * | 2012-03-29 | 2013-09-10 | 주식회사 바이오알파 | Tunable hyaluronic acid-calcium phosphate complexes with delivery rate of growth factors and preparation method thereof |
| US20160331738A1 (en) * | 2015-05-12 | 2016-11-17 | Incept, Llc | Drug delivery from hydrogels |
| CN107205922A (en) * | 2014-12-10 | 2017-09-26 | 因赛普特有限责任公司 | Hydrogel drug delivery implant |
| US20180318431A1 (en) * | 2015-12-09 | 2018-11-08 | The Regents Of The University Of California | Methods of treating an ocular disease or disorder |
| CN114366712A (en) * | 2022-01-25 | 2022-04-19 | 上海交通大学医学院附属第九人民医院 | Pharmaceutical gel mixture for treating choroidal neovascularization |
-
2022
- 2022-11-15 CN CN202211422822.XA patent/CN115671036A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| CN102144961A (en) * | 2003-09-18 | 2011-08-10 | 参天制药株式会社 | Transscleral delivery |
| US20090226519A1 (en) * | 2005-04-19 | 2009-09-10 | Charles Claude | Hydrogel bioscaffoldings and biomedical device coatings |
| CN101426531A (en) * | 2006-04-21 | 2009-05-06 | 东兴药品工业株式会社 | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation |
| US20090275668A1 (en) * | 2006-04-21 | 2009-11-05 | Toko Yakuhin Kogyo Dabushiki Kaisha | Sprayable Gel-Type Skin/Mucosa-Adhesive Preparation and Administration System Using the Preparation |
| KR101306748B1 (en) * | 2012-03-29 | 2013-09-10 | 주식회사 바이오알파 | Tunable hyaluronic acid-calcium phosphate complexes with delivery rate of growth factors and preparation method thereof |
| CN107205922A (en) * | 2014-12-10 | 2017-09-26 | 因赛普特有限责任公司 | Hydrogel drug delivery implant |
| US20160331738A1 (en) * | 2015-05-12 | 2016-11-17 | Incept, Llc | Drug delivery from hydrogels |
| US20180318431A1 (en) * | 2015-12-09 | 2018-11-08 | The Regents Of The University Of California | Methods of treating an ocular disease or disorder |
| CN114366712A (en) * | 2022-01-25 | 2022-04-19 | 上海交通大学医学院附属第九人民医院 | Pharmaceutical gel mixture for treating choroidal neovascularization |
Non-Patent Citations (1)
| Title |
|---|
| HUIQIN GAO等: "Injectable Anti-Inflammatory Supramolecular Nanofiber Hydrogel to Promote Anti-VEGF Therapy in Age-Related Macular Degeneration Treatment", 《ADV. MATER》, vol. 35, no. 2, 9 November 2022 (2022-11-09), pages 1 - 19 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7082599B2 (en) | Methods and Devices for the Treatment of Eye Disorders in Human Subjects | |
| ES2897560T3 (en) | Treatment of choroidal neovascularization | |
| AU604236B2 (en) | Intraocular dosage compositions and method of use | |
| RU2572707C2 (en) | Ophthalmic drops with difluprednate for treating macular oedema | |
| JPH08502033A (en) | Method for treating eye disease using TGF-β | |
| JP2017061467A5 (en) | ||
| CN116077665A (en) | Compounds for the treatment of ophthalmic diseases and disorders | |
| US20070027102A1 (en) | Methods and compositions for treating macular degeneration | |
| CA3025258C (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| WO2014203183A1 (en) | Use of a vegf antagonist in treating macular edema | |
| WO2019040397A1 (en) | A method for treating or preventing neovascular age-related macular degeneration | |
| UA122117C2 (en) | Methods of treatment of ocular conditions with a sustained drug delivery implant | |
| CN115671036A (en) | Gel medicine for treating fundus and intraocular diseases | |
| CN114929245A (en) | anti-C5 agent for the treatment of dry age-related macular degeneration (AMD) or geographic atrophy secondary to dry AMD | |
| KR20230007963A (en) | Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin | |
| RU2659144C1 (en) | Method for treatment of cataract in patients with active neovascular diseases of macula | |
| EP2418279A1 (en) | Injectable pharmaceutical composition for preventing, stabilising and/or inhibiting pathological neovascularization-related conditions | |
| RU2714193C1 (en) | Method of treating inflammatory or dystrophic eye diseases | |
| LeHoang et al. | Primate model of uveoretinitis and vasculitis/experimental autoimmune uveoretinitis induced in cynomolgus monkeys by retinal s antigen | |
| Peterson et al. | Sustained ocular delivery of bevacizumab using densomeres in rabbits: Effects on molecular integrity and bioactivity. Transl Vis Sci Technol. 2023; 12 (3): 28 | |
| Peterson et al. | Sustained ocular delivery of bevacizumab using densomeres in rabbits: effects on molecular integrity and bioactivity | |
| RU2515550C1 (en) | Method of treating cataract in patients with pseudoexfoliation syndrome | |
| KALDIRIM et al. | Intravitreal Dexamethasone Implant in the Treatment of Pseudophakic Cystoid Macular Edema or Irvine-Gass Syndrome | |
| Sheu | Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to endogenous endophthalmitis | |
| Bikbov et al. | Action features of the implant with dexamethasone on indicators of retinal vein occlusions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |